HLA-C and neoplasm: CAR-T cells are genetically engineered to express a single-chain variable fragment (scFv) specifically targeting tumor-associated antigens on the surface of T cells, enabling the elimination of tumor cells independently of major histocompatibility complex (MHC) recognition (6, 7).